CL2020002943A1 - Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020 - Google Patents

Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020

Info

Publication number
CL2020002943A1
CL2020002943A1 CL2020002943A CL2020002943A CL2020002943A1 CL 2020002943 A1 CL2020002943 A1 CL 2020002943A1 CL 2020002943 A CL2020002943 A CL 2020002943A CL 2020002943 A CL2020002943 A CL 2020002943A CL 2020002943 A1 CL2020002943 A1 CL 2020002943A1
Authority
CL
Chile
Prior art keywords
application
inhibitors
methods
mcl
macrocyclic
Prior art date
Application number
CL2020002943A
Other languages
English (en)
Inventor
Zhi-Fu Tao
Xilu Wang
Aaron Kunzer
Gerard Sullivan
Wilfried Braje
George Doherty
Katja Jantos
Cheng Ji
Andrew Judd
Anthony Mastracchio
Xiaohong Song
Andrew Souers
Jesse Teske
Michael Wendt
Thomas Penning
Andreas Kling
Frauke Pohlki
Chunqiu Lai
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of CL2020002943A1 publication Critical patent/CL2020002943A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona compuestos de la Fórmula en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos, que son útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de la Fórmula (I).
CL2020002943A 2017-08-15 2020-11-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020 CL2020002943A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545853P 2017-08-15 2017-08-15
US201762555475P 2017-09-07 2017-09-07
US201862692663P 2018-06-30 2018-06-30

Publications (1)

Publication Number Publication Date
CL2020002943A1 true CL2020002943A1 (es) 2021-03-12

Family

ID=65362347

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020000363A CL2020000363A1 (es) 2017-08-15 2020-02-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso.
CL2020002943A CL2020002943A1 (es) 2017-08-15 2020-11-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020000363A CL2020000363A1 (es) 2017-08-15 2020-02-12 Inhibidores macrocíclicos de mcl-1 y métodos de uso.

Country Status (21)

Country Link
US (3) US10676485B2 (es)
EP (2) EP3652184A1 (es)
JP (1) JP2020531433A (es)
KR (1) KR20200041942A (es)
CN (1) CN111818917A (es)
AU (1) AU2018316620A1 (es)
BR (1) BR112020003180A2 (es)
CA (1) CA3073112A1 (es)
CL (2) CL2020000363A1 (es)
CO (1) CO2020002678A2 (es)
CR (1) CR20200124A (es)
EC (1) ECSP20018703A (es)
IL (1) IL272681A (es)
MX (1) MX2020001717A (es)
PH (1) PH12020500327A1 (es)
RU (1) RU2020110517A (es)
SG (2) SG11202001182QA (es)
TW (1) TW201920194A (es)
UA (1) UA126586C2 (es)
UY (1) UY37843A (es)
WO (1) WO2019035911A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414390B2 (en) 2017-09-07 2022-08-16 Hutchison Medipharma Limited Cycloolefin substituted heteroaromatic compounds and their use
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272599B (en) 2017-08-15 2022-08-01 Agios Pharmaceuticals Inc Pyruvate kinase modulators and their use
WO2019035911A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE
US20200239494A1 (en) * 2017-08-15 2020-07-30 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
AU2018317836A1 (en) * 2017-08-15 2020-03-19 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
BR112021023229A2 (pt) 2019-05-20 2022-05-31 Servier Lab Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
IL303079A (en) 2020-11-24 2023-07-01 Novartis Ag Antibody-drug conjugates inhibiting MCL-1 and methods of using them
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
EP4351657A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101667822B1 (ko) 2008-04-30 2016-10-19 내셔날 헬스 리서치 인스티튜트 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI742074B (zh) 2016-04-22 2021-10-11 瑞典商阿斯特捷利康公司 Mcl-1抑制劑及其使用方法
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
IL266198B2 (en) 2016-10-28 2023-11-01 Servier Lab Liposomal formulation for use in cancer treatment
EP3567043B1 (en) 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AU2018317836A1 (en) * 2017-08-15 2020-03-19 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
US20200239494A1 (en) * 2017-08-15 2020-07-30 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
WO2019035911A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE
CN107573360B (zh) 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414390B2 (en) 2017-09-07 2022-08-16 Hutchison Medipharma Limited Cycloolefin substituted heteroaromatic compounds and their use
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Also Published As

Publication number Publication date
WO2019035911A1 (en) 2019-02-21
KR20200041942A (ko) 2020-04-22
US20190144465A1 (en) 2019-05-16
MX2020001717A (es) 2020-10-08
AU2018316620A1 (en) 2020-03-12
US10676485B2 (en) 2020-06-09
BR112020003180A2 (pt) 2020-09-15
TW201920194A (zh) 2019-06-01
EP3988555A1 (en) 2022-04-27
UY37843A (es) 2019-03-29
US20200325153A1 (en) 2020-10-15
IL272681A (en) 2020-03-31
US20230183261A1 (en) 2023-06-15
JP2020531433A (ja) 2020-11-05
UA126586C2 (uk) 2022-11-02
CN111818917A (zh) 2020-10-23
SG11202001182QA (en) 2020-03-30
CA3073112A1 (en) 2019-02-21
EP3652184A4 (en) 2020-05-20
SG10202106345VA (en) 2021-07-29
RU2020110517A (ru) 2021-09-16
CR20200124A (es) 2020-09-28
CO2020002678A2 (es) 2020-08-10
RU2020110517A3 (es) 2022-03-23
CL2020000363A1 (es) 2020-06-12
ECSP20018703A (es) 2020-04-22
EP3652184A1 (en) 2020-05-20
PH12020500327A1 (en) 2020-10-12

Similar Documents

Publication Publication Date Title
CL2020002943A1 (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso. solicitud divisional de solicitud n° 363-2020
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY37844A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
DOP2022000117A (es) Inhibidores de kras g12c
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
CO2018011064A2 (es) Inhibidores de bromodominios
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
CY1121060T1 (el) Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EA201692298A1 (ru) Производные карбоксамидов
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CU24543B1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок